(Q84174712)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Michael R Mattern

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Jian Wu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Benjamin Nicholson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

17 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

Biochimica et Biophysica Acta

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

1823

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

2014-2021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22610084%20AND%20SRC:MED&resulttype=core&format=json

Tumour suppression: disruption of HAUSP gene stabilizes p53

1 February 2020

cites work

1 reference

12 December 2020

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

12 December 2020

Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes

1 reference

12 December 2020

Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells

1 reference

12 December 2020

A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

1 reference

12 December 2020

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme

1 reference

12 December 2020

Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme

1 reference

12 December 2020

Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues

1 reference

12 December 2020

Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts

1 reference

12 December 2020

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

1 reference

12 December 2020

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

1 reference

12 December 2020

Will the ubiquitin system furnish as many drug targets as protein kinases?

1 reference

12 December 2020

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

1 reference

12 December 2020

Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors

1 reference

12 December 2020

Molecular pathways: targeting proteasomal protein degradation in cancer

1 reference

12 December 2020

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

1 reference

12 December 2020

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

1 reference

12 December 2020

Missing the target: ubiquitin ligase drugs stall

1 reference

12 December 2020

A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome

1 reference

12 December 2020

A dynamic role of HAUSP in the p53-Mdm2 pathway

1 reference

12 December 2020

Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.

1 reference

12 December 2020

Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes

1 reference

12 December 2020

The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications

1 reference

12 December 2020

The development of proteasome inhibitors as anticancer drugs

1 reference

12 December 2020

Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes

1 reference

12 December 2020

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

1 reference

12 December 2020

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

1 reference

12 December 2020

Deubiquitinating enzymes as novel anticancer targets

1 reference

12 December 2020

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

12 December 2020

Molecular mechanisms of bortezomib resistant adenocarcinoma cells

1 reference

12 December 2020

The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites.

1 reference

12 December 2020

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

12 December 2020

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

1 reference

12 December 2020

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

12 December 2020

Recent advances in p53 research and cancer treatment

1 reference

12 December 2020

Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway

1 reference

12 December 2020

Novel proteasome inhibitors to overcome bortezomib resistance

1 reference

12 December 2020

Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets

1 reference

12 December 2020

Mechanistic studies of substrate-assisted inhibition of ubiquitin-activating enzyme by adenosine sulfamate analogues

1 reference

12 December 2020

Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib

1 reference

12 December 2020

Cardiotoxicity of the anticancer therapeutic agent bortezomib.

1 reference

12 December 2020